CAMBRIDGE, Mass. , Aug. 07, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics , Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer , Ph.D., M.A., M.Phil ., as Chief Business Officer (CBO).
Categories
Recent Posts
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
- Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
- Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference
- Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)